Ayala Pharmaceuticals Inc
ADXS.PK
$0.57
Closing
▼-11.70%
1D
▼-14.54%
YTD
Market cap
$24.30M
52 week high
$1.95
52 week low
$0.50
Volume
9,468
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$24.30M
Analysts' Rating
HOLD
Price Target (Mean)
-
Total Analysts
1
P/E
Operating Margin
0.00%
Beta
1.68
Revenue Growth (Annual)
-92.28%
52 week high
$1.95
52 week low
$0.50
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The Company’s lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). The Company’s product candidates, AL101 and AL102, are being developed as potent, selective, small molecule gamma secretase inhibitors (GSIs). AL101 and AL102 targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. The product candidates have the potential to transform treatment outcomes for patients suffering from rare and aggressive cancers. The Company’s Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.
